TL;DR
This multicenter randomized trial found that combining tacrolimus with either sirolimus or mycophenolate mofetil (MMF) resulted in comparable renal function at 6 months post-transplant. While both regimens offered similar graft and patient survival, the sirolimus combination led to more adverse events like hypercholesterolemia and higher rates of premature withdrawal, suggesting MMF might be a more tolerable alternative for some patients.
What Problem Does This Paper Address?
Following a kidney transplant, patients require immunosuppressive drugs to prevent their new kidney from being rejected by their immune system. Tacrolimus is a cornerstone of these regimens, but it's often combined with other drugs to enhance its effectiveness and manage potential side effects. Two common combinations are tacrolimus with sirolimus (Tac/SRL) and tacrolimus with mycophenolate mofetil (Tac/MMF). While both are effective, there's ongoing debate about their comparative efficacy, particularly regarding renal function preservation, and their safety profiles. Specifically, concerns exist about sirolimus potentially exacerbating tacrolimus-induced nephrotoxicity (kidney damage), while MMF has its own set of side effects. This study aimed to directly compare these two regimens in a large, multicenter setting to determine if one offered superior renal function and to thoroughly assess their safety and tolerability.
Methods
This was a prospective, randomized, multicenter, phase III clinical trial involving 51 centers across 13 European countries. Adult patients (18-60 years old) undergoing primary renal transplantation or retransplantation were randomized in a 1:1 ratio to receive either:
- Tacrolimus/Sirolimus (Tac/SRL): Tacrolimus was administered with a fixed-dose sirolimus regimen. Notably, targeted tacrolimus trough levels were intentionally set lower after day 14 in the Tac/SRL group to mitigate potential nephrotoxicity.
- Tacrolimus/Mycophenolate Mofetil (Tac/MMF): Tacrolimus was combined with MMF.
The primary endpoint was renal function at 6 months, assessed using the Cockcroft-Gault formula for creatinine clearance. Secondary endpoints included biopsy-confirmed acute rejection (BCAR), patient and graft survival, and the incidence of adverse events. Statistical analysis focused on comparing the mean creatinine clearance between groups, with a predefined margin for non-inferiority.
Datasets
Not discussed in the paper. The study involved data collected from patients enrolled in the clinical trial.
Key Insights and Ideas
- Non-inferiority Confirmed: The study successfully demonstrated that the Tac/SRL regimen is non-inferior to the Tac/MMF regimen in terms of preserving renal function at 6 months post-transplant. This is a crucial finding for clinicians deciding on immunosuppressive strategies.
- Dosing Strategy Matters: The researchers implemented a novel fixed-dose sirolimus strategy and adjusted tacrolimus trough levels, particularly lowering them in the Tac/SRL group after the initial post-operative period. This approach likely contributed to the comparable renal function observed, potentially mitigating some of the previously reported nephrotoxicity concerns with sirolimus.
- Tolerability Trade-offs: While renal function was similar, the safety profiles differed. The Tac/SRL group experienced a higher incidence of hypercholesterolemia and a significantly higher rate of premature withdrawal due to adverse events. Conversely, the Tac/MMF group saw more instances of CMV infection, leukopenia, and diarrhea. This highlights that the choice of regimen involves a trade-off between different types of adverse events.
- Steroid Withdrawal Challenges: Adherence to protocol-defined steroid withdrawal was suboptimal in both groups, with a significant portion of patients still on steroids at later time points. This suggests that achieving steroid-free immunosuppression remains a clinical challenge.
Key Results
- Renal Function: At 6 months, mean creatinine clearance was comparable between groups: 66.4 mL/min (SE 1.4) for Tac/SRL and 65.2 mL/min (SE 1.3) for Tac/MMF (among completers).
- Acute Rejection: Biopsy-confirmed acute rejection (BCAR) rates were similar, with 15.1% in the Tac/SRL group and 12.3% in the Tac/MMF group.
- Survival: Graft survival at 6 months was 92.7% for Tac/SRL and 93.3% for Tac/MMF. Patient survival was high in both groups, at 99.0%.
- Adverse Events:
- Premature withdrawal due to adverse events was twice as high in the Tac/SRL group (15.1%) compared to the Tac/MMF group (6.3%).
- Hypercholesterolemia was more frequent with Tac/SRL (P < .05).
- CMV infection, leukopenia, and diarrhea were more frequent with Tac/MMF (P < .05, and P < .001 for CMV and leukopenia).
- De novo diabetes mellitus incidence was lower with Tac/SRL (17.8%) compared to Tac/MMF (24.8%).
Limitations and Future Work
- Study Duration: The 6-month duration of the study limits the ability to project long-term renal function or graft survival. The authors acknowledge that longer follow-up is needed to fully assess the long-term benefits and risks of each regimen.
- Steroid Withdrawal: The low adherence to steroid withdrawal protocols means that the study cannot definitively comment on the safety of early steroid withdrawal at 3 months.
- Imputation of Missing Data: While a sensitivity analysis was performed on patients with available data at 6 months, the authors note that an analysis using imputation for missing data might provide additional insights, though they suspect it wouldn't alter the primary conclusion.
- Future Directions: The study design makes it difficult to pinpoint specific variables that might mitigate or accelerate nephrotoxicity. Future research could focus on identifying such factors and exploring longer-term outcomes and the impact of different dosing strategies. The authors also suggest that further investigation into the feasibility of fixed-dose sirolimus reduction schemas without compromising efficacy is warranted.
Summary updated